Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease

Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease

Abstract Objective HTLV‐1 infection causes HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), resulting in loss of motor function. In this Phase 2 trial, we assessed the efficacy and safety of l‐arginine in patients with HAM/TSP. Methods This open‐label, single‐arm, Phase 2 study e...

Full description

Bibliographic Details
Main Authors: Satoshi Nozuma, Eiji Matsuura, Yuichi Tashiro, Ryusei Nagata, Masahiro Ando, Yu Hiramatsu, Yujiro Higuchi, Yusuke Sakiyama, Akihiro Hashiguchi, Kumiko Michizono, Keiko Higashi, Toshio Matsuzaki, Daisuke Kodama, Masakazu Tanaka, Yoshihisa Yamano, Takashi Moritoyo, Ryuji Kubota, Hiroshi Takashima
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.51715

Internet

https://doi.org/10.1002/acn3.51715

Similar Items